The Impact of Infant Bacille Calmette-Guérin Vaccination on the Immunogenicity of Other Vaccines: A Randomized Exploratory Study.
Maytum A. et al, (2024), Pediatr Infect Dis J
Serum HCoV-spike specific antibodies do not protect against subsequent SARS-CoV-2 infection in children and adolescents.
Ratcliffe H. et al, (2023), iScience, 26
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus.
Fidler S. et al, (2023), Clin Infect Dis, 76, 201 - 209
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.
Shaw RH. et al, (2022), Lancet Respir Med, 10, 1049 - 1060
Community seroprevalence of SARS-CoV-2 in children and adolescents in England, 2019-2021.
Ratcliffe H. et al, (2022), Arch Dis Child
Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd protection from the UK MenACWY programme.
Carr JP. et al, (2022), Clin Microbiol Infect
An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females.
Marchevsky NG. et al, (2022), EBioMedicine, 81
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV.
Ogbe A. et al, (2022), JCI Insight, 7
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
Clemens SAC. et al, (2021), Nature Communications, 12
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.
Feng S. et al, (2021), Nat Med, 27, 2032 - 2040
Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trial.
Davis K. et al, (2021), Lancet Infect Dis, 21, 688 - 696
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
Emary KRW. et al, (2021), Lancet, 397, 1351 - 1362
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993
Understanding the reactogenicity of 4CMenB vaccine: Comparison of a novel and conventional method of assessing post-immunisation fever and correlation with pre-release in vitro pyrogen testing.
Valente Pinto M. et al, (2020), Vaccine, 38, 7834 - 7841
Gene expression profiling reveals insights into infant immunological and febrile responses to group B meningococcal vaccine.
O'Connor D. et al, (2020), Mol Syst Biol, 16